




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 8




FIG. 9




FIG. 10

Construct	Production level (mg/L)	Monomeric molecule	Host	Endotoxin (EU/mg)
TPTL11	42	94.08%	CHO-K1	0.3
TPTL12	42	95.34%	CHO-K1	0.3
TPTL13	47.25	94.94%	CHO-K1	0.3
TPTL14	38.9	96.45%	CHO-K1	0.3
TPTL15	45	93.68%	CHO-K1	0.2
TPTL16	36	94.02%	CHO-K1	0.2
TPTL17	33.3	94.62%	CHO-K1	0.3
TPTL18	43.3	93.74 %	CHO-K1	0.3
TPTL19	28.8	92.61%	CHO-K1	0.3
TPTL20	45.15	93.38%	CHO-K1	0.2

FIG. 11




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 12F




FIG. 12G




FIG. 12H




FIG. 12I




FIG. 12J




FIG. 12K




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E




FIG. 13F




FIG. 13G




FIG. 13H




FIG. 13I




FIG. 13J




FIG. 13K




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 14F




FIG. 14G




FIG. 14H




FIG. 14I




FIG. 14J




FIG. 14K

	TIGIT				LAG-3			PD-1			
	Affinity (nM)	Cell binding (EC ₅₀ nM)	Ligand competition (IC ₅₀ nM)	Affinity (nM)	Cell binding (EC ₅₀ nM)	Ligand competition (IC ₅₀ nM)	Affinity (nM)	Cell binding (EC ₅₀ nM)	Ligand competition (IC ₅₀ nM)		
									PD-L1	PD-L2	
TPTL11	0.35	4.277	12.73	1.1	5.734	31.78	22	14.1	27.08	26.37	
TPTL12	0.41	2.681	8.214	0.91	4.979	39.36	27	12.26	11.45	20.09	
TPTL13	0.31	5.055	9.567	1.3	5.781	23.41	9.7	10.34	21.81	18.61	
TPTL14	0.42	6.288	13.98	3.4	11.07	12.68	11	14.64	26.58	26.95	
TPTL15	0.42	4.436	8.379	3.9	4.2	28.23	26	10.46	23.74	21.54	
TPTL16	0.38	10.12	15.54	2.2	4.366	23.31	25	12.05	29.52	27.29	
TPTL17	0.37	3.996	9.191	2.0	5.567	35.71	10	12.53	26.29	21.22	
TPTL18	2.3	6.202	23.6	3.7	5.528	40.53	11	7.025	17.16	15.47	
TPTL19	2.3	6.912	23.59	4.5	6.377	22.67	10	7.75	10.03	12.5	
TPTL20	2.2	7.325	23.92	2.2	3.023	14.78	10	4.295	13.5	8.181	
AS19584VH28 HCAb	0.44	4.989	8.613	NA			NA		NA		
V _H H2 HCAb	NA			0.45	1.819	11.04	NA				
Keytruda	NA			NA			12	4.424	13.04	12.77	

FIG. 15

Sample	Concentration	HPLC purity	Tagg (°C)
TPTL-11	5.09 mg/ml	~96.21%	53.3
TPTL-12	4.95 mg/ml	~95.99%	65.3
TPTL-13	5.28 mg/ml	~94.28%	65.8
TPTL-14	5.46 mg/ml	~94.23%	64.4
TPTL-15	5.14 mg/ml	~96.83%	67.9
TPTL-16	5.44 mg/ml	~96.51%	63.9
TPTL-17	5.46 mg/ml	~95.13%	63.8
TPTL-18	5.24 mg/ml	~94.99%	67.9
TPTL-19	4.98 mg/ml	~93.28%	60.9
TPTL-20	4.96 mg/ml	~92.23%	58.8

FIG. 16

Sample name	Concentrated Sample F&T Peak height	Recovery% (accroding to the peak height)
TPTL-11 control	801.42	100%
TPTL-11 FT	775.52	97%
TPTL-12 control	697.27	100%
TPTL-12 FT	694.53	100%
TPTL-13 control	758.77	100%
TPTL-13 FT	717.89	95%
TPTL-14 control	828.54	100%
TPTL-14 FT	777.13	94%
TPTL-15 control	604.5	100%
TPTL-15 FT	607.96	101%
TPTL-17 control	610.4	100%
TPTL-17 FT	565.19	93%
TPTL-18 control	855.2	100%
TPTL-18 FT	733.58	85.7%
TPTL-19 control	805.31	100%
TPTL-19 FT	607.61	75%
TPTL-20 control	827.62	100%
TPTL-20 FT	673.26	81.3%

FIG.17




FIG.18A




FIG. 18B




FIG. 18C